Skip to content
value.today

Prellis Biologics, Inc

Total raised
$47 M
4 rounds on record
Latest round
$17 M
Jun 2022
First round on record
Jun 2017
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prellis Biologics, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2022$17 MNo. 4$10 to $50 million

Prellis Biologics, Inc: Raise no. 4, Jun 2022

Investors in this round

19 investors had bought by the notice of Jul 6, 2022: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $35 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Melanie Matheu · Executive Officer, Director
  • Alex Morgan · Director
  • Lei Meng · Director
  • Michael Marks · Director
  • Sean O'Sullivan · Director
  • Shaun Holt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Melanie Matheu, Ceo. Newest notice filed Jul 6, 2022. Read the notice at the SEC.

equitySEC
Jul 2021$19 MNo. 3$10 to $50 million

Prellis Biologics, Inc: Raise no. 3, Jul 2021

Investors in this round

9 investors had bought by the notice of Jul 14, 2021: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Melanie Matheu · Executive Officer, Director
  • Alex Morgan · Director
  • Arvind Gupta · Director
  • Michael Marks · Director
  • Shaun Holt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Melanie Matheu, Chief Executive Officer. Newest notice filed Jul 14, 2021. Read the notice at the SEC.

equitySEC
Mar 2019$9 MNo. 2$2 to $10 million

Prellis Biologics, Inc: Raise no. 2, Mar 2019

Investors in this round

11 investors had bought by the notice of Mar 27, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Melanie Matheu · Executive Officer, Director
  • Arvind Gupta · Director
  • Rohit Sharma · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Melanie Matheu, Chief Executive Officer. Newest notice filed Mar 27, 2019. Read the notice at the SEC.

equitySEC
Jun 2017$2 MNo. 1Under $2 million

Prellis Biologics, Inc: Raise no. 1, Jun 2017

Investors in this round

2 investors had bought by the notice of Jul 10, 2017: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Melanie Matheu · Executive Officer, Director
  • Noelle Mullin · Executive Officer, Director
  • Arvind Gupta · Director
  • Rohit Sharma · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Melanie Matheu, Chief Executive Officer. Newest notice filed Jul 10, 2017. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prellis Biologics, Inc chose not to state its revenue in its newest notice of a funding round (Jul 2022).

    SEC Form D · Jul 2022

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jul 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Prellis Biologics, Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prellis Biologics, Inc
NameRoleNamed in
Melanie MatheuExecutive officerJul 2022
Noelle MullinExecutive officerJul 2017
Alex MorganDirectorJul 2022
Lei MengDirectorJul 2022
Melanie MatheuDirectorJul 2022
Michael MarksDirectorJul 2022
Sean O'SullivanDirectorJul 2022
Shaun HoltDirectorJul 2022
Arvind GuptaDirectorJul 2021
Rohit SharmaDirectorMar 2019
Noelle MullinDirectorJul 2017